MYGN
Myriad Genetics, Inc.
MYGN offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over MYGN overall, supported by lower modeled downside and stronger valuation.
MYGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Under pressure |
MYGN's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
MYGN PE Valuation
MYGN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
MYGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect MYGN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over MYGN on the outlook, with more favorable earnings and revenue expectations.
MYGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$2.96 |
| Q2 2026 | -$1.20 | +$3.08 |
| Q1 2026 | -$4.31 | -$3.19 |
| Q4 2025 | -$3.95 | -$2.54 |
| Q3 2025 | -$4.33 | -$3.05 |
| Q2 2025 | -$4.28 | -$2.49 |
| Q1 2025 | -$1.12 | +$1.68 |
| Q4 2024 | -$1.41 | +$1.77 |
MYGN is still losing money, but far less than before: $1.37 per share over the past year, against $4.33 at its worst in late 2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over MYGN on earnings quality, reporting a profit while its opponent remains loss making.
MYGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $202.7M | -1.5% |
| Q2 2026 | $190.7M | -11% |
| Q1 2026 | $200.4M | +2.3% |
| Q4 2025 | $209.8M | -0.4% |
| Q3 2025 | $205.7M | -3.6% |
| Q2 2025 | $213.1M | +0.8% |
| Q1 2025 | $195.9M | -3.1% |
| Q4 2024 | $210.6M | +7.1% |
MYGN's revenue grew through 2023 and has held roughly level since: $203M last quarter, down 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -8.3 points |
| Q2 2026 | -20% | +134 points |
| Q1 2026 | -15% | -0.5 points |
| Q4 2025 | -2.7% | +16 points |
| Q3 2025 | -11% | -1.9 points |
| Q2 2025 | -154% | -137 points |
| Q1 2025 | -15% | -1 points |
| Q4 2024 | -19% | -2.5 points |
MYGN's operating margin was −20% last quarter, down 8.3 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over MYGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over MYGN on profitability, with a higher operating margin.
MYGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5M | -131% |
| Q2 2026 | -$8.3M | +$5.3M |
| Q1 2026 | -$15.7M | +$600K |
| Q4 2025 | $10.6M | +61% |
| Q3 2025 | $21.1M | +2914% |
| Q2 2025 | -$13.6M | -623% |
| Q1 2025 | -$16.3M | +$2.3M |
| Q4 2024 | $6.6M | +$61.3M |
MYGN has burned cash in most quarters: −$20M over the past year, against −$2M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over MYGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
MYGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +900K shares |
| 1 year | +2.8% | +2.6M shares |
| 3 years | +17% | +13.8M shares |
| 5 years | +17% | +14.2M shares |
| Available history | +29% | +21.3M shares |
MYGN has 96M diluted shares, up 2.8% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over MYGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
MYGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 3.3x | Elevated |
MYGN's net debt is about 3.3 years of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
MYGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.3 | Overbought |
MYGN's weekly RSI is 57 (neutral) and its Stochastic is 80 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
MYGN PE vs Healthcare Sector
MYGN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
MYGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.10 | 11% above |
| 20 week MA | $4.52 | 26% above |
| 50 week MA | $4.88 | 16% above |
| 100 week MA | $6.48 | 12% below |
| 200 week MA | $13.8 | 59% below |
MYGN has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 59% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over MYGN on trend strength, trading above more of its moving averages.
MYGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.8 | $18.4 | -31% |
| 2021 | $18.4 | $27.3 | +48% |
| 2022 | $27.3 | $15.6 | -43% |
| 2023 | $15.6 | $19.1 | +22% |
| 2024 | $19.1 | $13.4 | -30% |
| 2025 | $13.4 | $6.48 | -52% |
| 2026 YTD | $6.48 | $5.68 | -12% |
MYGN has finished lower in four of the last six years. It's down 12% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over MYGN on returns for 2026, with the stronger performance.